As a key leader and member of the Avanir commercial organization, this individual will lead the marketing of NUEDEXTA (dextromethorphan and quinidine) capsules for the pseudobulbar affect (PBA) indication to health care providers including neurologists, psychiatrists, long-term care providers, select PCPs and other allied health care professionals in the US market.